Abnormal expression of CEBPB promotes the progression of renal cell carcinoma through regulating the generation of IL-6

Background: The CCAAT/enhancer-binding protein beta (CEBPB), a transcription factor regulating immune and inflammatory responses, has been implicated in the pathogenesis of various malignancies. However, its specific regulatory mechanism in renal cell carcinoma (RCC) remains poorly understood. Metho...

Full description

Bibliographic Details
Main Authors: Yaoqiang Ren, Wenke Guo, Baoping Qiao
Format: Article
Language:English
Published: Elsevier 2023-10-01
Series:Heliyon
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844023073838
_version_ 1797646567480492032
author Yaoqiang Ren
Wenke Guo
Baoping Qiao
author_facet Yaoqiang Ren
Wenke Guo
Baoping Qiao
author_sort Yaoqiang Ren
collection DOAJ
description Background: The CCAAT/enhancer-binding protein beta (CEBPB), a transcription factor regulating immune and inflammatory responses, has been implicated in the pathogenesis of various malignancies. However, its specific regulatory mechanism in renal cell carcinoma (RCC) remains poorly understood. Methods: The expression of CEBPB was detected in RCC cells and tissues using qRT-PCR, western blotting and immunohistochemistry. ELISA assay was used to detect the immune factors regulated by CEBPB in supernatants. Additionally, western blotting was employed to measure the phosphorylation level of STAT3 and the expression levels of its downstream target genes. Results: CEBPB was found to be overexpressed in both RCC tissues and cell lines, and its higher expression was associated with a lower survival rate. In RCC cells, CEBPB enhances the expression of IL6, consequently promoting the phosphorylation of STAT3 and the expression of its downstream target genes. This mechanism ultimately facilitates tumor progression. Conclusions: The dysregulated expression of CEBPB facilitates RCC progression through the IL6/STAT3 pathway. CEBPB is a potential diagnostic markers and a novel effective therapeutic target for RCC patients.
first_indexed 2024-03-11T15:03:27Z
format Article
id doaj.art-20d4daf5652b405d9ee72e8c50c4d17f
institution Directory Open Access Journal
issn 2405-8440
language English
last_indexed 2024-03-11T15:03:27Z
publishDate 2023-10-01
publisher Elsevier
record_format Article
series Heliyon
spelling doaj.art-20d4daf5652b405d9ee72e8c50c4d17f2023-10-30T06:05:28ZengElsevierHeliyon2405-84402023-10-01910e20175Abnormal expression of CEBPB promotes the progression of renal cell carcinoma through regulating the generation of IL-6Yaoqiang Ren0Wenke Guo1Baoping Qiao2Departments of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaDepartment of Thyroid Surgery, Fenyang Hospital of Shanxi Province, Lüliang, Shanxi, ChinaDepartments of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; Corresponding author. Departments of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.Background: The CCAAT/enhancer-binding protein beta (CEBPB), a transcription factor regulating immune and inflammatory responses, has been implicated in the pathogenesis of various malignancies. However, its specific regulatory mechanism in renal cell carcinoma (RCC) remains poorly understood. Methods: The expression of CEBPB was detected in RCC cells and tissues using qRT-PCR, western blotting and immunohistochemistry. ELISA assay was used to detect the immune factors regulated by CEBPB in supernatants. Additionally, western blotting was employed to measure the phosphorylation level of STAT3 and the expression levels of its downstream target genes. Results: CEBPB was found to be overexpressed in both RCC tissues and cell lines, and its higher expression was associated with a lower survival rate. In RCC cells, CEBPB enhances the expression of IL6, consequently promoting the phosphorylation of STAT3 and the expression of its downstream target genes. This mechanism ultimately facilitates tumor progression. Conclusions: The dysregulated expression of CEBPB facilitates RCC progression through the IL6/STAT3 pathway. CEBPB is a potential diagnostic markers and a novel effective therapeutic target for RCC patients.http://www.sciencedirect.com/science/article/pii/S2405844023073838CEBPBRenal cell carcinomaIL6STAT3
spellingShingle Yaoqiang Ren
Wenke Guo
Baoping Qiao
Abnormal expression of CEBPB promotes the progression of renal cell carcinoma through regulating the generation of IL-6
Heliyon
CEBPB
Renal cell carcinoma
IL6
STAT3
title Abnormal expression of CEBPB promotes the progression of renal cell carcinoma through regulating the generation of IL-6
title_full Abnormal expression of CEBPB promotes the progression of renal cell carcinoma through regulating the generation of IL-6
title_fullStr Abnormal expression of CEBPB promotes the progression of renal cell carcinoma through regulating the generation of IL-6
title_full_unstemmed Abnormal expression of CEBPB promotes the progression of renal cell carcinoma through regulating the generation of IL-6
title_short Abnormal expression of CEBPB promotes the progression of renal cell carcinoma through regulating the generation of IL-6
title_sort abnormal expression of cebpb promotes the progression of renal cell carcinoma through regulating the generation of il 6
topic CEBPB
Renal cell carcinoma
IL6
STAT3
url http://www.sciencedirect.com/science/article/pii/S2405844023073838
work_keys_str_mv AT yaoqiangren abnormalexpressionofcebpbpromotestheprogressionofrenalcellcarcinomathroughregulatingthegenerationofil6
AT wenkeguo abnormalexpressionofcebpbpromotestheprogressionofrenalcellcarcinomathroughregulatingthegenerationofil6
AT baopingqiao abnormalexpressionofcebpbpromotestheprogressionofrenalcellcarcinomathroughregulatingthegenerationofil6